Calidi Biotherapeutics Partners with TransferAI to Enhance Drug Submission Process
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Should l Buy CLDI?
Source: NASDAQ.COM
- Partnership Announcement: Calidi Biotherapeutics has partnered with TransferAI to enhance the efficiency of the investigational new drug submission process for CLD-401, aiming to expedite treatment for non-small cell lung cancer and other tumors.
- Platform Utilization: The RedTail platform developed by Calidi employs enveloped oncolytic viruses to improve targeted delivery to tumors and modify the tumor microenvironment, thereby enhancing treatment efficacy and potentially increasing patient survival rates.
- AI Integration: By leveraging TransferAI's Sofie platform, Calidi will streamline research coordination, cross-referencing, drafting, and review activities, optimizing regulatory workflows and reducing development time and costs.
- Clinical Trial Advancement: Calidi plans to rapidly demonstrate the impact of systemic virotherapies in Phase 1 studies, advancing the development of CLD-401 and CLD-501 while broadening the applications of the RedTail platform to enhance market competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLDI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLDI
About CLDI
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Calidi Biotherapeutics Partners with TransferAI to Enhance Drug Submission Process
- Partnership Announcement: Calidi Biotherapeutics has partnered with TransferAI to enhance the efficiency of the investigational new drug submission process for CLD-401, aiming to expedite treatment for non-small cell lung cancer and other tumors.
- Platform Utilization: The RedTail platform developed by Calidi employs enveloped oncolytic viruses to improve targeted delivery to tumors and modify the tumor microenvironment, thereby enhancing treatment efficacy and potentially increasing patient survival rates.
- AI Integration: By leveraging TransferAI's Sofie platform, Calidi will streamline research coordination, cross-referencing, drafting, and review activities, optimizing regulatory workflows and reducing development time and costs.
- Clinical Trial Advancement: Calidi plans to rapidly demonstrate the impact of systemic virotherapies in Phase 1 studies, advancing the development of CLD-401 and CLD-501 while broadening the applications of the RedTail platform to enhance market competitiveness.
See More
Calidi Biotherapeutics Reports FY Loss and Public Offering
- Financial Loss: Calidi Biotherapeutics reported a FY GAAP EPS of -$5.95, indicating significant challenges in profitability that could undermine investor confidence and negatively impact stock performance.
- Cash Flow Status: As of December 31, 2025, the company had approximately $5.6 million in cash, a substantial decrease from $9.6 million in 2024, reflecting liquidity constraints that may limit future operational and R&D investments.
- Public Offering Plan: Calidi plans a $5.2 million underwritten public offering, which aims to strengthen its capital base; however, market reactions may be subdued due to the company's current financial condition, leading to a decline in share price.
- Restricted Cash Situation: The company maintained $0.2 million in restricted cash as of December 31, 2025, indicating a cautious approach to cash utilization that may affect its financial flexibility in the short term.
See More
Calidi Biotherapeutics Accelerates CLD-401 Clinical Trial Initiation
- Clinical Trial Partnership: Calidi has partnered with Australia's Avance Clinical to rapidly initiate the first-in-human clinical trial for CLD-401, which is expected to significantly enhance the drug's market entry speed and strengthen the company's competitive position in oncology.
- Positive FDA Feedback: The company received encouraging feedback from the FDA through Type D interactions, confirming that its manufacturing and analytical approaches align with FDA guidance, with plans to file an IND by the end of 2026, paving the way for CLD-401's clinical development.
- Successful Fundraising: Calidi raised $6 million in gross proceeds from a public offering in Q1 2026 and an additional $0.5 million from ATM sales in Q4 2025, bolstering its financial position and extending its cash runway for ongoing projects.
- Increased R&D Spending: Research and development expenses reached $2.4 million in Q4 2025, up from $1.8 million in the same period of 2024, reflecting the company's ongoing investment in advancing CLD-401 and other projects to meet market demand for innovative therapies.
See More
CALIDI BIOTHERAPEUTICS INC REPORTS Q4 NET LOSS OF $0.57 PER SHARE
Company Overview: Calidi Biotherapeutics is a biotechnology company focused on developing innovative therapies.
Financial Performance: The company reported a net loss of $0.57 per share for the fourth quarter.
See More
Calidi Partners with Avance for First-in-Human Trial of CLD-401
- Partnership for Clinical Trial: Calidi Biotherapeutics has partnered with Avance Clinical to rapidly initiate a first-in-human clinical trial for its investigational candidate CLD-401, marking a significant advancement in addressing high unmet medical needs in non-small cell lung cancer and other tumor types.
- Trial Objectives: The trial aims to evaluate the safety, pharmacodynamics, and efficacy of CLD-401 as a monotherapy in patients with solid tumors who have exhausted all other therapeutic options, indicating a potential positive impact on this patient population.
- FDA Filing Plans: Calidi plans to file an IND for CLD-401 with the FDA in 2026, demonstrating the company's confidence in the drug's development and laying the groundwork for future market access.
- Stock Price Reaction: Following the announcement of the partnership, Calidi's stock rose 3.65% to $0.30 in pre-market trading, reflecting market optimism regarding the collaboration and its potential outcomes.
See More
CALIDI Biotherapeutics Forms Partnership with Avance Clinical to Streamline Australian Regulatory Approval and Expedite CLD-401 Clinical Trials Launch
Partnership Announcement: Calidi Biotherapeutics has announced a partnership with Avance Clinical to facilitate clinical trials in Australia.
Regulatory Approval: The partnership aims to accelerate the initiation of clinical trials for CLD-401, a therapeutic product.
Focus on Clinical Trials: The collaboration will leverage Avance Clinical's expertise to navigate the regulatory landscape in Australia.
Goal of the Initiative: The initiative is designed to expedite the development and testing of innovative therapies in the Australian market.
See More
Calidi Biotherapeutics Partners with TransferAI to Enhance Drug Submission Process
- Partnership Announcement: Calidi Biotherapeutics has partnered with TransferAI to enhance the efficiency of the investigational new drug submission process for CLD-401, aiming to expedite treatment for non-small cell lung cancer and other tumors.
- Platform Utilization: The RedTail platform developed by Calidi employs enveloped oncolytic viruses to improve targeted delivery to tumors and modify the tumor microenvironment, thereby enhancing treatment efficacy and potentially increasing patient survival rates.
- AI Integration: By leveraging TransferAI's Sofie platform, Calidi will streamline research coordination, cross-referencing, drafting, and review activities, optimizing regulatory workflows and reducing development time and costs.
- Clinical Trial Advancement: Calidi plans to rapidly demonstrate the impact of systemic virotherapies in Phase 1 studies, advancing the development of CLD-401 and CLD-501 while broadening the applications of the RedTail platform to enhance market competitiveness.
See More
Calidi Biotherapeutics Reports FY Loss and Public Offering
- Financial Loss: Calidi Biotherapeutics reported a FY GAAP EPS of -$5.95, indicating significant challenges in profitability that could undermine investor confidence and negatively impact stock performance.
- Cash Flow Status: As of December 31, 2025, the company had approximately $5.6 million in cash, a substantial decrease from $9.6 million in 2024, reflecting liquidity constraints that may limit future operational and R&D investments.
- Public Offering Plan: Calidi plans a $5.2 million underwritten public offering, which aims to strengthen its capital base; however, market reactions may be subdued due to the company's current financial condition, leading to a decline in share price.
- Restricted Cash Situation: The company maintained $0.2 million in restricted cash as of December 31, 2025, indicating a cautious approach to cash utilization that may affect its financial flexibility in the short term.
See More
Calidi Biotherapeutics Accelerates CLD-401 Clinical Trial Initiation
- Clinical Trial Partnership: Calidi has partnered with Australia's Avance Clinical to rapidly initiate the first-in-human clinical trial for CLD-401, which is expected to significantly enhance the drug's market entry speed and strengthen the company's competitive position in oncology.
- Positive FDA Feedback: The company received encouraging feedback from the FDA through Type D interactions, confirming that its manufacturing and analytical approaches align with FDA guidance, with plans to file an IND by the end of 2026, paving the way for CLD-401's clinical development.
- Successful Fundraising: Calidi raised $6 million in gross proceeds from a public offering in Q1 2026 and an additional $0.5 million from ATM sales in Q4 2025, bolstering its financial position and extending its cash runway for ongoing projects.
- Increased R&D Spending: Research and development expenses reached $2.4 million in Q4 2025, up from $1.8 million in the same period of 2024, reflecting the company's ongoing investment in advancing CLD-401 and other projects to meet market demand for innovative therapies.
See More
CALIDI BIOTHERAPEUTICS INC REPORTS Q4 NET LOSS OF $0.57 PER SHARE
Company Overview: Calidi Biotherapeutics is a biotechnology company focused on developing innovative therapies.
Financial Performance: The company reported a net loss of $0.57 per share for the fourth quarter.
See More
Calidi Partners with Avance for First-in-Human Trial of CLD-401
- Partnership for Clinical Trial: Calidi Biotherapeutics has partnered with Avance Clinical to rapidly initiate a first-in-human clinical trial for its investigational candidate CLD-401, marking a significant advancement in addressing high unmet medical needs in non-small cell lung cancer and other tumor types.
- Trial Objectives: The trial aims to evaluate the safety, pharmacodynamics, and efficacy of CLD-401 as a monotherapy in patients with solid tumors who have exhausted all other therapeutic options, indicating a potential positive impact on this patient population.
- FDA Filing Plans: Calidi plans to file an IND for CLD-401 with the FDA in 2026, demonstrating the company's confidence in the drug's development and laying the groundwork for future market access.
- Stock Price Reaction: Following the announcement of the partnership, Calidi's stock rose 3.65% to $0.30 in pre-market trading, reflecting market optimism regarding the collaboration and its potential outcomes.
See More
CALIDI Biotherapeutics Forms Partnership with Avance Clinical to Streamline Australian Regulatory Approval and Expedite CLD-401 Clinical Trials Launch
Partnership Announcement: Calidi Biotherapeutics has announced a partnership with Avance Clinical to facilitate clinical trials in Australia.
Regulatory Approval: The partnership aims to accelerate the initiation of clinical trials for CLD-401, a therapeutic product.
Focus on Clinical Trials: The collaboration will leverage Avance Clinical's expertise to navigate the regulatory landscape in Australia.
Goal of the Initiative: The initiative is designed to expedite the development and testing of innovative therapies in the Australian market.
See More
